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Abstract 
Background: Cancer-associated fibroblast (CAF) is the most studied element of the tumor microenvironment, 
although no relationship has been identified between expression of their related proteins and the metastasis site. The 
purpose of this study was to investigate the expression of CAF related proteins and their implications according to the 
metastasis site in metastatic breast cancer.
Methods: Immunohistochemical staining was used to evaluate the expression of CAF related proteins (podoplanin, 
prolyl 4-hydroxylase, FAPα, S100A4, PDGFRα, PDGFRβ, and NG2) in tissue microarrays from 132 cases of metastatic 
breast cancer (bone metastasis: 32 cases, brain metastasis: 38 cases, liver metastasis: 10 cases, and lung metastasis: 52 
cases). Breast cancer subtypes were classified as luminal A, luminal B, HER-2, and triple negative breast cancer, accord-
ing to the immunohistochemical staining results for estrogen and progesterone receptors, HER-2, and Ki-67 and FISH 
results for HER-2. Tumors were classified as desmoplastic, sclerotic, normal-like, and inflammatory type, according to 
the histologic findings from the tumor stroma.
Results: Various CAF related protein expression profiles were observed, according to the metastasis site. For bone 
metastasis, the expression of stromal podoplanin, S100A4, and PDGFRα was significantly high. For lung metastasis, 
the expression of stromal PDGFRβ was significantly elevated (p < 0.001). For liver metastasis, significantly reduced 
expression of stromal S100A4 (p = 0.002) and PDGFRα (p = 0.011) was observed. Expression of CAF related proteins 
also differed according to the stromal phenotype. Desmoplastic stroma exhibited significantly elevated expression 
of stromal podoplanin (p < 0.001), S100A4 (p < 0.001), PDGFRα (p = 0.010), and PDGFRβ (p = 0.021). Inflammatory 
stroma exhibited significantly elevated expression of stromal FAPα (p = 0.044) and significantly reduced stromal 
S100A4 expression (p < 0.001). Sclerotic stroma exhibited significantly elevated tumoral FAPα (p = 0.005) expression. 
For lung metastasis, shorter overall survival was significantly related to tumoral podoplanin expression (p = 0.006), 
stromal podoplanin expression (p = 0.018), tumoral prolyl 4-hydroxylase negativity (p = 0.016), and tumoral PDGFRα 
expression (p = 0.001).
Conclusion: For metastatic breast cancer, significant differences were observed in the expression of CAF related 
proteins, according to the metastasis site and stromal histologic phenotype.
Keywords: Breast cancer, Cancer-associated fibroblast, Molecular subtype, Stroma
© 2015 Kim et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided 
you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate 
if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Breast cancers are associated with high morbidity and 
mortality rates, as they are prone to distant metastasis. 
The major metastasis sites for breast cancer are the lungs, 
brain, liver, and bone [1, 2], and most studies have been 
evaluated in brain and bone metastasis [3–8]. The most 
common mechanism for tumor metastasis is a recipro-
cal interaction between the tumor cell and host tissue, 
which is achieved by adhesion, proteolysis, invasion, and 
angiogenesis [2, 9]. In addition, the importance of the 
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tumor microenvironment in the process of metastasis 
has recently emerged. Among the various elements of the 
tumor microenvironment, cancer-associated fibroblast 
(CAF) is the most studied, and are currently considered 
most important element in this microenvironment [10]. 
Various proteins have been suggested as markers for 
CAF, including α-SMA [11], tenascin-C [12], chondroitin 
sulfate proteoglycan (NG2) [13], platelet-derived growth 
factor receptors (PDGFR)α/β [14], fibroblast activation 
protein (FAP) [15], podoplanin [16], prolyl 4-hydroxy-
lase [17], and fibroblast-specific protein (FSP)-1/S100A4 
[13]. Therefore, it appears that CAF may consist of vari-
ous functional subtypes. In one recent study, CAF were 
classified into various subsets, such as FAPα type, FSP1 
type, PDGFRα type, and PDGFRβ type [18]. These 
subsets all showed different characteristics; this sup-
ports the hypothesis that CAF are comprised of diverse 
phenotypes.
To explain the unique metastasis pattern for each can-
cer, the “seed and soil” hypothesis has been proposed, 
which explains how a specific tumor (the seed) survives 
in a specific visceral organ (the soil) [19]. Similarly, differ-
ent characteristic findings have been reported according 
to the site of metastasis for metastatic breast cancer. For 
example, previous studies have demonstrated that brain 
metastasis was related to young age, estrogen-receptor 
(ER) negativity, prior lung metastasis, HER-2 overexpres-
sion, epidermal growth factor receptor (EGFR) overex-
pression, and the basal subtype [5–7]. In addition, bone 
metastasis was related to a lower histologic grade, ER 
positivity, ER positivity and progesterone receptor (PR) 
negativity, strand growth patterns, and the presence of 
fibrotic foci in invasive ductal carcinoma [4, 20, 21]. Thus, 
as the characteristics of metastatic breast cancer differed 
according to the site of metastasis, it is likely that there 
are similar phenotypic differences for CAF, although few 
studies have evaluated this topic. Therefore, the purpose 
of this study was to investigate the expression of CAF 
related proteins and their implications, according to the 
metastasis site in metastatic breast cancer.
Methods
Patient selection
This study retrospectively reviewed cases of invasive 
primary breast cancer with metastasis to distant organs 
(liver, lungs, brain, and bone) from the records of the 
Department of Pathology, Severance Hospital, South 
Korea. Only patients that were diagnosed with invasive 
ductal carcinoma were included, which provided a total 
of 132 cases, including 49 cases with paired primary and 
metastasized tumors. All slides from these cases were 
reviewed, and the pathologic parameters were evaluated 
by 2 pathologists (JSK and WHJ). The histologic grade 
was assessed using the Nottingham grading system [22]. 
The study design was reviewed and approved by our 
Institutional Review Board.
For the invasive ductal carcinomas, the tumor stroma 
was classified according to the microscopic findings as 
desmoplastic type (stroma consisting of cellular fibro-
blast/myofibroblast proliferation), sclerotic type (stroma 
with fibrotic collagenous components and minimal cel-
lular components), pauci-stromal type (minimal stromal 
tissue near the tumor), or inflammatory type (stroma 
consisting of inflammatory cells, such as lymphocytes).
Tissue microarrays
On H&E-stained slides of tumors, a representative area 
was selected, and a corresponding spot was marked on 
the surface of a paraffin block. Using a biopsy needle, 
the selected area was extracted, and a 3-mm tissue core 
was placed into a 6 × 5 array. Tissues from the invasive 
tumor were extracted, and more than two tissue cores 
were extracted to minimize extraction bias. Each tissue 
core was assigned a unique tissue microarray location 
number, which was linked to a database that contained 
the other clinicopathological data.
Immunohistochemistry
The antibodies and dilutions that were used for the 
immunohistochemistry are listed in Additional file  1: 
Table  S1. All immunohistochemistry was performed 
using the formalin-fixed and paraffin-embedded tissue 
sections. Briefly, 5-μm sections were obtained using a 
microtome, transferred onto adhesive slides, and dried 
at 62°C for 30  min. After incubation with the primary 
antibodies, immunodetection was performed using 
biotinylated anti-mouse immunoglobulin, followed by 
peroxidase-labeled streptavidin using a labeled strepta-
vidin biotin kit with 3,3′-diaminobenzidine chromogen 
as the substrate. The primary antibody incubation step 
was omitted in the negative control. Positive control tis-
sue was used as per the manufacturer’s recommendation. 
The slides were subsequently counterstained with Harris 
hematoxylin.
Interpretation of immunohistochemical staining
All immunohistochemical markers were assessed via light 
microscopy. A cut-off value of ≥1% positively stained 
nuclei was used to define ER and PR positivity [23]. 
HER-2 staining was analyzed according to the Ameri-
can Society of Clinical Oncology/College of American 
Pathologists guidelines, using the following categories: 
0 =  no immunostaining; 1+ =  weak incomplete mem-
branous staining in <10% of the tumor cells; 2+ = com-
plete membranous staining, either uniform or weak, 
in ≥10% of the tumor cells; and 3+ =  uniform intense 
Page 3 of 11Kim et al. J Transl Med  (2015) 13:222 
membranous staining in ≥30% of the tumor cells [24]. 
For our analysis, HER-2 immunostaining was considered 
positive when strong (3+) membranous staining was 
observed, whereas 0 or 1+ cases were considered nega-
tive. Cases with 2+ HER-2 expression were evaluated for 
HER-2 amplification via fluorescent in situ hybridization 
(FISH).
Immunohistochemical markers for podoplanin, prolyl 
4-hydroxylase, FAPα, S100A4, PDGFRα, PDGFRβ, and 
NG2 were assessed via light microscopy. The stained 
slides were evaluated semi-quantitatively, as reported 
previously [25]. In brief, tumor and stromal cell staining 
was assessed as 0 = negative or weak immunostaining in 
<1% of the tumor/stroma, 1 = focal expression in 1–10% 
of the tumor/stroma, 2  =  positive in 11–50% of the 
tumor/stroma, or 3 = positive in 51–100% of the tumor/
stroma. These evaluations were performed for the entire 
tumor area, and scores of 2–3 were defined as positive for 
our analysis.
Tumor phenotype classification
In this study, we classified the phenotypes of breast can-
cer according to the immunohistochemical results for 
ER, PR, HER-2, Ki-67, and FISH results for HER-2, as 
follows: luminal A type = ER and/or PR positive, HER-2 
negative, and a Ki-67 labeling index (LI) of <14%; HER-2 
negative luminal B type  =  ER and/or PR positive and 
Ki-67 LI ≥14%; HER-2 positive luminal B type = ER and/
or PR positive, and HER-2 overexpressed and/or ampli-
fied; HER-2 overexpression type = ER and PR negative, 
and HER-2 overexpressed or/and amplified; and triple 
negative breast cancer (TNBC) type =  negative for ER, 
PR, and HER-2 [26].
Statistical analysis
Data were analyzed using SPSS for Windows (version 
12.0, SPSS Inc., Chicago, IL, USA). Chi Square tests and 
Fisher’s exact tests were used for categorical variables, 
respectively. When analyzing data with multiple com-
parisons, we used the Bonferroni multiple comparison 
procedure to generate a corrected p value. Statistical sig-
nificance was set at a p value of <0.05. Kaplan–Meier sur-
vival curves and log-rank statistics were used to evaluate 
the time to tumor recurrence and overall survival. Multi-
variate regression analysis was performed using the Cox 
proportional hazards model.
Results
Characteristics of the breast cancer cases
Among the 132 patients, 32 (24.2%) had bone metasta-
sis, 38 (28.8%) had brain metastasis, 10 (7.6%) had liver 
metastasis, and 52 (39.4%) had lung metastasis. The pro-
portion of patients with ER positivity and PR positivity 
was significantly elevated in bone and liver metastasis 
(p  <  0.001), and the proportion of patients with HER-2 
positivity was significantly elevated in brain metastasis 
(p = 0.047). A higher proportion of luminal A type was 
observed in bone and liver metastasis, and a higher pro-
portion of TNBC type was observed in brain and lung 
metastasis (p  <  0.001) (Additional file  1: Table  S2). The 
immunohistochemical staining results and clinicopatho-
logic characteristics of patients with metastatic breast 
cancer were determined in the metastatic tumor.
Clinicopathological features according to the stromal 
phenotype
The stromal phenotype was analyzed, and 38 (28.8%) 
patients was classified as having desmoplastic stroma, 9 
(6.8%) had inflammatory stroma, 45 (34.1%) had pauci-
stroma, and 40 (30.3%) had sclerotic stroma. The clinico-
pathological characteristics were investigated according to 
the stromal phenotype and the only significant differences 
in stromal phenotype was according to the metastatic site 
(p < 0.001). The proportion of inflammatory and sclerotic 
stroma was higher in lung metastasis, desmoplastic stroma 
was more common in bone metastasis, and pauci-stroma 
was more common in brain metastasis (Table 1).
Expression of CAF related proteins according to the 
metastasis site
Analysis of the expression of CAF related proteins 
in metastatic tumor according to the metastasis site 
revealed no expression of PDGFRβ and NG2 in the 
tumor cells, and no expression of prolyl 4-hydroxylase in 
the stromal component. However, significant differences 
were observed in the expression of tumoral podoplanin 
(p  =  0.008), stromal podoplanin (p  =  0.047), tumoral 
prolyl 4-hydroxylase (p  =  0.001), stromal S100A4 
(p =  0.002), stromal PDGFRα (p =  0.011), and stromal 
PDGFRβ (p  <  0.001) according to the metastasis site. 
Stromal podoplanin, S100A4, and PDGFRα expression 
was elevated in bone metastasis, while tumoral podopla-
nin and stromal PDGFRβ expression was elevated in lung 
metastasis. In liver metastasis, tumoral prolyl 4-hydrox-
ylase expression was elevated, while stromal S100A4 
and PDGFRα expression was reduced. Expression of 
tumoral podoplanin, stromal podoplanin, tumoral prolyl 
4-hydroxylase, stromal PDGFRα, and stromal PDGFRβ 
was reduced in brain metastasis (Figures 1, 2).
Analysis of the expression of CAF related proteins 
based on molecular subtype of each metastatic site 
revealed that stromal S100A4 (p  =  0.015) and tumoral 
PDGFRα (p = 0.037) was associated with bone metasta-
sis, tumoral prolyl 4-hydroxylase (p = 0.003) and tumoral 
S100A4 (p = 0.034) with brain metastasis, stromal podo-
planin (p = 0.019) and tumoral S100A4 (p = 0.019) with 
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liver metastasis, and tumoral PDGFRα (p =  0.034) and 
stromal PDGFRα (p = 0.042) with lung metastasis (Addi-
tional file 1: Table S3).
Expression of CAF related proteins according to the 
stromal phenotype
We also investigated the expression of CAF related pro-
teins according to the stromal phenotype, and observed 
significant differences in the expression of stromal podo-
planin (p  <  0.001), tumoral FAPα (p  =  0.005), stromal 
FAPα (p =  0.044), stromal S100A4 (p  <  0.001), stromal 
PDGFRα (p = 0.010), and stromal PDGFRβ (p = 0.021). 
Desmoplastic stroma exhibited high expression of stro-
mal podoplanin, S100A4, PDGFRα, and PDGFRβ, while 
inflammatory stroma exhibited high stromal FAPα and 
low tumoral FAPα and stromal S100A4 expression. 
Sclerotic stroma exhibited low stromal FAPα and high 
tumoral FAPα expression, while pauci-stroma exhibited 
low expression of stromal podoplanin, S100A4, PDGFRα, 
and PDGFRβ (Figures 3, 4).
Correlation of CAF related protein expression with primary 
and metastatic breast cancer
Significant differences were observed in the expression 
of stromal podoplanin (p  =  0.002) and tumoral pro-
lyl 4-hydroxylase (p =  0.039) in primary and metastatic 
breast cancer. They were positive in primary cancer, 
but negatively converted in metastasis site in 42.9 and 
22.9% cases, respectively (Figure 5). Each metastatic site-
specific analysis did not show any significant findings; 
metastatic tumors other than lung metastasis were not 
included in the analysis, because the number is too small.
Correlation between CAF related protein expression 
and the clinicopathological factors
The relationship between CAF related protein expres-
sion and the clinicopathological factors were investigated 
(Figure  6). Tumoral PDGFRα expression was associated 
with ER and PR negativity (p  <  0.001 and p  =  0.001, 
respectively). The stromal phenotype was associated with 
stromal podoplanin (p < 0.001) and S100A4 (p < 0.001) 
Table 1 Clinicopathological characteristics of the patients according to the breast cancer stromal histologic phenotype
Italic value indicates statistically significant (p < 0.05).
TNBC triple negative breast cancer.












 ≤50 68 (51.5) 21 (55.3) 5 (55.6) 25 (55.6) 17 (42.5)
 >50 64 (48.5) 17 (44.7) 4 (44.4) 20 (44.4) 23 (57.5)
ER 0.339
 Negative 63 (47.7) 20 (52.6) 6 (66.7) 22 (48.9) 15 (37.5)
 Positive 69 (52.3) 18 (47.4) 3 (33.3) 23 (51.1) 25 (62.5)
PR 0.060
 Negative 91 (68.9) 28 (73.7) 7 (77.8) 35 (77.8) 21 (52.5)
 Positive 41 (31.1) 10 (26.3) 2 (22.2) 10 (22.2) 19 (47.5)
HER-2 0.370
 Negative 89 (67.4) 28 (73.7) 4 (44.4) 29 (64.4) 28 (70.0)
 Positive 43 (32.6) 10 (26.3) 5 (55.6) 16 (35.6) 12 (30.0)
Molecular subtypes 0.063
 Luminal A 47 (35.6) 15 (39.5) 3 (33.3) 12 (26.7) 17 (42.5)
 Luminal B 23 (17.4) 3 (7.9) 0 (0.0) 11 (24.4) 9 (22.5)
 HER-2 27 (20.5) 7 (18.4) 5 (55.6) 8 (17.8) 7 (17.5)
 TNBC 35 (26.5) 13 (34.2) 1 (11.1) 14 (31.1) 7 (17.5)
Ki-67 LI (%) 0.139
 ≤14 91 (68.9) 31 (81.6) 6 (66.7) 26 (57.8) 28 (70.0)
 >14 41 (31.1) 7 (18.4) 3 (33.3) 19 (42.2) 12 (30.0)
Metastasis site <0.001
 Bone 32 (24.2) 18 (47.4) 0 (0.0) 4 (8.9) 10 (25.0)
 Brain 38 (28.8) 3 (7.9) 2 (22.2) 25 (55.6) 8 (20.0)
 Liver 10 (7.6) 0 (0.0) 0 (0.0) 0 (0.0) 10 (25.0)
 Lung 52 (39.4) 17 (44.7) 7 (77.8) 16 (35.6) 12 (30.0)
Patients death 44 (33.3) 15 (39.5) 3 (33.3) 14 (31.1) 12 (30.0) 0.815
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Figure 1 Expression of cancer-associated fibroblast related proteins according to the metastasis site. Stromal podoplanin, S100A4, and PDGFRα 
expression was elevated in bone metastasis, and stromal PDGFRβ expression was elevated in lung metastasis. In liver metastasis, stromal S100A4 
and PDGFRα expression was reduced. Inlet figures show the expression of CAF related proteins in fibroblast.
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expression, with the desmoplastic stroma exhibiting high 
stromal podoplanin and S100A4 expression.
Impact of CAF related protein expression on patient 
prognosis
When the impact of CAF related protein expression on 
patient prognosis was analyzed, no factor was associated 
with shorter overall survival (OS) in the univariate analy-
sis (Additional file 1: Table S4).
Discussion
Although no previous study has evaluated the expres-
sion of CAF related proteins according to the breast 
cancer metastasis site, the tumor stroma features are 
expected to be different, as different clinicopathological 
characteristics have been observed at different metas-
tasis sites [27]. Therefore, we analyzed the expression 
of CAF related proteins according to the breast cancer 
metastasis site, and observed various different expres-
sion patterns. For example, the stromal expression of 
podoplanin, S100A4, and PDGFRα was high in bone 
metastasis, while PDGFRβ expression was high in lung 
metastasis. The high expression of podoplanin, S100A4, 
and PDGFRα in the CAF of bone metastasis is likely 
explained the characteristics of the bone environment. 
In a previous study, different functional characteris-
tics were identified according to the CAF subtype [18], 
with PDGFRα and S100A4 types of CAF being related 
to macrophage infiltration and macrophage recruit-
ment [28, 29]. It has also been suggested that bone is 
relevant to macrophage recruitment, because it is one 
of the main hematopoietic organs. In addition, a pre-
vious study has reported high expression of S100A4 in 
adipocyte-derived fibroblasts, which are a major desmo-
plastic stroma component in breast cancer [30]. As bone 
has numerous adipocytes in the marrow tissue, CAFs 
derived from marrow tissue are expected to exhibit high 
S100A4 expression. The second probable mechanism for 
our observed differences in CAF related protein expres-
sion is the differences in the metastatic cancer cell. For 
example, previous reports have reported metastasis site-
specific characteristics in metastatic breast cancer, with 
bone metastasis exhibiting a lower histologic grade, ER 
positivity, ER positivity and PR negativity, strand growth 
patterns, and the presence of fibrotic foci in invasive 
ductal carcinoma [4, 20, 21]. As the tumor stroma char-
acteristics are formed via reciprocal interactions with 
cancer cells, various CAF phenotypes would also be 
expected if the cancer cell characteristics varied accord-
ing to the site of metastasis. In addition, we observed 
Figure 2 Expression of cancer-associated fibroblast related proteins in metastatic tumor according to the metastasis site. T tumor cell component, 
S stromal component.
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Figure 3 Expression of cancer-associated fibroblast related proteins according to the stromal phenotype. Desmoplastic stroma exhibited high 
expression of stromal podoplanin, S100A4, PDGFRα, and PDGFRβ, while inflammatory stroma exhibited high stromal FAPα expression. Sclerotic 
stroma exhibited high tumoral FAPα expression. Inlet figures show the expression of PDGFRα in cancer cells.
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that the pathologic characteristics varied according to 
the metastasis site.
Therefore, different CAF profile might have influenced 
the tumor molecular subtype as well as different organ. 
However, our study indicates that CAF profile seems 
to be more related to different organ rather than tumor 
molecular subtype according to the following findings. 
First, there was no significant association between the 
expressions of CAF related proteins and molecular sub-
type by correlation analysis. Second, to evaluate the asso-
ciation between different organ and tumor molecular 
subtype in CAF profile, additional CAF profile by molec-
ular subtype was evaluated according to metastatic site; 
if metastatic organ was identical, the items showing dif-
ferent expression of CAF related proteins by molecular 
subtype was fewer.
Figure 4 Expression of cancer-associated fibroblast related proteins in metastatic tumor according to the stromal phenotype. T tumor cell compo-
nent, S stromal component.
Figure 5 Correlation between cancer-associated fibroblast related protein expression for primary and metastatic cancer. Significant differences 
were observed in the expression of stromal podoplanin and tumoral prolyl 4-hydroxylase in primary and metastatic breast cancer.
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In lung metastasis, the CAF expression of PDGFRβ was 
high, and previous studies have reported a relationship 
between high interstitial fluid pressure and PDGFRβ type 
CAF [31]. Because the lungs have distinct histologic fea-
tures, if a cancer cell metastasizes to a small interstitial 
tissue among the alveoli, it might encounter high inter-
stitial fluid pressure, thereby promoting PDGFRβ expres-
sion. Furthermore, lung metastasis is known to be related 
to TNBC type; therefore, further investigation is needed 
to determine whether tumor cell characteristics might 
influence the CAF phenotype.
In this study, we demonstrated that CAF related pro-
tein expression varied according to the stromal histologic 
type, with desmoplastic stroma having high podoplanin, 
S100A4, PDGFRα, and PDGFRβ expression, and inflam-
matory stroma having high FAPα expression. Although 
a previous study classified breast cancer tumor stroma 
according to their histologic findings [32], few study has 
compared the differences in CAF according to the histo-
logic findings, therefore these results are not comparable. 
In addition, it has been noted that CAF markers have 
specific and unique features. For example, in breast can-
cer, the desmoplastic response appears to be mediated by 
PDGF-AA signaling in PDGFRα type CAF [33]; this pos-
sibility is compatible with our findings. In addition, FAPα 
has been reported to possess an immunomodulatory 
function [18], which is consistent with our finding that 
inflammatory stroma has high FAPα expression. How-
ever, further investigation is needed to reveal the specific 
relationship between the tumor stroma histology and 
CAF characteristics.
The clinical implication of our findings is that CAF 
might be a potential anti-cancer therapeutic target. This 
target is particularly attractive, as it is genetically stable 
(relative to the cancer cell), exhibits distinct epigenetic 
changes within normal stromal cells, and can be tar-
geted throughout the neoplasm process, as it supports 
and accompanies the cancer cell through the whole neo-
plasm spectrum [34]. Interestingly, several preclinical 
studies have targeted the CAF markers that we evaluated, 
and they reported that agents targeting CAF were effec-
tive in tumor inhibition [35–38]. However, to develop 
an effective cancer therapy, CAF-targeted treatments 
should exploit agents that target the specific CAF pheno-
type, and further studies are needed to determine which 
agents most effectively target each phenotype.
Figure 6 Correlation between the expressions of cancer-associated fibroblast related proteins and various clinicopathological factors.
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Conclusion
In conclusion, the expression of CAF related proteins in 
stroma varies according to the breast cancer metastasis 
site and the stromal histologic phenotype.
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